Here, we demonstrate that CAV-2–mediated expression of exogenous NaV1.1 activity, via a codon-modified SCN1A ORF, can significantly improve comorbidities in juvenile and adult DS mice, ameliorate the epileptic phenotypes, correct background ECoG activity, and improve cognitive functions. This evidence concerns the gene CAV2 and Dravet syndrome.